A
Apimeds Pharmaceuticals US Inc.
Biotechnology: Pharmaceutical Preparations company
Key Metrics of Apimeds Pharmaceuticals US Inc.
Revenue—FY 2023
Operating income−$747K
Net profit−$778K
Shareholders' equity$31.9K
Market cap$4.6MAPUS · $3.01
Competitors10identified
About Apimeds Pharmaceuticals US Inc.
Sectors
Company details
- Founded
- 2025
- Listed
- NYSE: APUS (since 2025)
Operational Areas of Apimeds Pharmaceuticals US Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameApimeds Pharmaceuticals US Inc.
TickerAPUS
ExchangeNYSE
CountryUnited States
SEC CIK0001894525
Listed since2025
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
APUS · NYSE · SEC CIK 0001894525
Last price · 02 Nov 2026
$3.01
−6.23%
Market cap$4.6M
P/E—On FY 2023 diluted EPS
Volume21,485
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPO—Listed 2025
APUS share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Apimeds Pharmaceuticals US Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
 Becton Dickinson |
Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | twistbioscience.com | 2018 | United States |
Similar companies
E
Elanco Animal Health IncorporatedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medtronic plc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
S
Summit Therapeutics Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
ICON plc (ICLR)Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
Charles River Laboratories International Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
A
Ascendis Pharma A/S Ordinary SharePharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medpace Holdings Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
I
Insmed IncorporatedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.